KOL Insight Archives | Page 11 of 14 | Report Store

Acne Prescribing Practices Pulse Survey

$599.00

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.

November 29, 2016

Find out more

Multiple Sclerosis KOL Insight Interview

$599.00

Multiple Sclerosis KOL Insight Interview

October 28, 2014

Find out more

Congestive Heart Failure Pulse Survey

$599.00

The study was just closed early, as LCZ696 increased time to first occurrence of either

cardiovascular death or heart failure hospitalization, though details have not been released.

We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

assumptions about what the study found.

April 1, 2014

Find out more

Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.

April 1, 2014

Find out more

2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

$599.00

Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.

January 28, 2015

Find out more

Breast Cancer Pulse Survey

$599.00

Drugs and drug candidates discussed:

palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor

April 23, 2014

Find out more

Neuromodulation KOL Interview

$599.00

Neuromodulation KOL Interview

February 5, 2015

Find out more

Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

May 13, 2014

Find out more

Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

October 31, 2014

Find out more

Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

July 25, 2014

Find out more

Retinal Disorders (AMD and DME) Pulse

$599.00

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

October 27, 2014

Find out more

Ebola KOL Interview #1

$599.00

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

November 2, 2014

Find out more

2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

May 26, 2015

Find out more

Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview

$599.00

Biomedtracker interviewed a nephrologist based in the US Midwest to determine his views on the drugs in development for diabetic nephropathy/diabetic kidney disease.

May 13, 2016

Find out more

2016 Biomedtracker Post-EASL Hepatitis C Survey

$599.00

We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.

May 16, 2016

Find out more